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Abstract 
 
Despite the increasing laboratory research in the growing field of 3D bioprinting there are 
few reports of successful translation into surgical practice. This review outlines the 
principles of 3D bioprinting including software and hardware processes, biocompatible 
technological platforms and suitable bioinks. The advantages of 3D bioprinting over 
traditional tissue engineering techniques in assembling cells, biomaterials and 
biomolecules in a spatially controlled manner to reproduce native tissue macro-, micro- 
and nano-architecture is discussed, together with an overview of current progress in 
bioprinting tissue types relevant for plastic and reconstructive surgery. If successful, this 
platform technology has the potential to biomanufacture autologous tissue for 
reconstruction obviating the need for donor sites or immunosuppression. The biological, 
technological and regulatory challenges are highlighted, with strategies to overcome these 
using an integrated approach from the fields of engineering, biomaterial science, cell 
biology and reconstructive microsurgery. 
 
Keywords: 3D bioprinting, biomaterials, bioinks, biofabrication 
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Introduction 
 
Technological innovations in plastic and reconstructive surgery in the 20th and 21st 
century have revolutionized the specialty. Despite the developments in microsurgery 
and transplantation, we are still confronted with shortcomings relating to the 
availability and morbidity of donor sites. Three-dimensional (3D) biomanufacture of 
tissue would remove the morbidity associated with the use of autologous tissue or 
long-term immunosuppression. The surgical community worldwide is becoming 
increasingly aware of this research landscape and The American Society of Plastic 
surgeons recently highlighted the importance of translating bench research in tissue 
engineering into clinical practice1. As a clinical specialty, plastic surgeons are well 
placed to be leaders in the developing field of 3D biomanufacture. A growing cohort of 
research active plastic surgeons, skilled in vascularisation, tissue viability/transfer and 
the manipulation of cells, will be well placed in the future to transplant tissue 
engineered constructs to treat a broad range of reconstructive challenges2.  
 
Traditional 3D printing 
 
3D printing, also known as “rapid prototyping”, “solid free form fabrication”, “additive 
manufacturing” and “layered manufacturing” was first described by Charles Hull in 19863, 
using imaging data to design and print 3D objects layer by layer. This technique allows 
mass customization, which undermines economies of scale and is predicted to 
revolutionize every sector of society4. This technology has already begun to influence the 
field of plastic and reconstructive surgery; from creating 3D models for training and 
surgical planning to manufacture of implants and personalized prostheses5.  
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3D bioprinting 
 
The ability to print biological “inks”, rather than the plastic and metal inks of traditional 3D 
printing, has resulted in the birth of the new bioprinting research field6. The global 3D 
bioprinting market was estimated to be $487 million in 2014 and this is predicted to reach 
$1.82 billion by 20227. A bioprinter is used to dispense ‘bioinks’, consisting of cells, 
scaffolds and biomolecules, in a spatially controlled manner rather than traditional tissue-
engineering methods of assembly, consisting of non-specific cell seeding of scaffolds8. 3D 
bioprinting, by controlling the nano-, micro- and macrostructure, may replicate complex 
native-like tissue architecture more faithfully in the laboratory9. This would allow 
biomanufacture of physiologically relevant multicellular tissue constructs on demand with 
direct translational potential obviating the need for autologous tissue harvest10 which could 
transform reconstructive surgery11. 
 
The success of this platform technology ultimately depends on not only on the process 
itself, but answers to the fundamental scientific questions regarding the correct blend of 
cell source, suitable scaffold and ideal microenvironment2. Given the future potential and 
synergistic goals of bioprinting and reconstructive surgery in restoring ‘form and 
function’12, we propose that plastic surgeons should be well versed in the principles and 
intimately involved in the future developments of 3D bioprinting to ensure it maintains 
clinical applicability.  
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Methods 
 
Literature Search and Study Selection 
 
A literature review of publications in English was performed on Pubmed, Medline and Em-
base using the terms (3D printing OR bioprinting OR additive manufacturing OR biomanu-
facture) AND (reconstructive surgery OR surgery OR tissue biomanufacture). Publications 
from January 1970 to December 2016 and in English were included in the review. In the 
first screening, the abstracts from the literature search were scrutinized against the inclu-
sion and exclusion criteria. Only those articles relating to 3D bioprinting of tissues directly 
relevant to plastic and reconstructive surgery were included (bone, cartilage, muscle, 
nerve, fat, and skin) and those relating to solid organ bioprinting were excluded. Articles 
relating to traditional 3D printing of non-organic material were also excluded.  The articles 
whose abstracts fulfilled the inclusion criteria were then retrieved and the references in the 
relevant articles were also screened.  
 
Data Extraction and Analysis 
  
We assessed the types of 3D printing technologies that are suitable for printing biological 
materials (Table 1) as well as the principles for using 3D bioprinting over more traditional 
tissue assembly techniques (Table 2). Of the 50 publications of relevant bioprinted tissue 
we identified the cell type, biomaterial and bioprinting technique used, whether the studies 
were in vivo or in vitro as well as final outcome.  
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Principles 
 
Bioprinting process 
 
3D bioprinting is an automated, computer-aided deposition of cells, biomaterials and 
biomolecules6 which has been made possible by recent advances in engineering, material 
science, computer science and cell biology. Printer hardware is controlled by software to 
precisely deposit biological materials in a layer by layer fashion (Figure 1). In its simplest 
form, a 3D bioprinter uses a syringe to deposit biomaterial and cells (between 2 and 20 
million cells per mL) in the correct xyz coordinates by computer controlled stepper motors 
to create the structure required (Figure 2). As the material is deposited, the speed and 
volume can be altered to ensure that object resolution is maintained. Bioprinted structures 
are then cultured in a bioreactor under specific conditions in order to produce 
physiologically relevant engineered tissue. 
 
Traditional 3D printing is relatively simple and can be done from a home computer with the 
correct software. Digital image data can be acquired from pre-existing templates or 
designed manually using open source Autodesk Inventor software (Figure 3). For more 
complex shapes or custom made implants 3D digital data is acquired from computed 
tomography (CT), magnetic resonance imaging (MRI) or laser scanning (Figure 1). This 
volumetric data can be manipulated by computer-aided design, computer-aided 
manufacturing (C D-CAM), Mimic or open source Tinkercard software and then converted 
into standard tessellation language (STL)13. The STL file must be further processed by 
“slicer” software (e.g. Cura, Slic3r) that converts the model into layers and produces a G-
code file. Following these G-code instructions, various commercially available, numerically 
controlled printers e.g. Ultimaker 2, lay down specific volumes of material required in 
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successive 2D horizontal layers. Whilst all this is relatively straightforward for traditional 3D 
printing, when it comes to bioprinting, there are no standardized hardware or software 
platforms due to the heterogeneity of biomaterials and cells that scientists are currently 
investigating. In our laboratory, we use extrusion-based bioprinters (Figure 2), custom 
designed and manufactured by our in-house engineering team running Cura software but 
other commercially available 3D bioprinters such as The 3D Bioplotter (EnvisionTEC, 
Gladbeck, Germany) and NovoGen MMX (Organovo and Invetech) also exist.  
 
Bioprinting technologies 
 
3D bioprinting technologies are classified depending on whether they use direct-write i.e. 
biomaterials are transferred by direct contact (e.g. extrusion based, laser guided direct 
writing, dip pen nanolithography), or resist-write technology i.e. where the structure is 
formed remotely by selective polymerization which traps the desired biomaterials (e.g. ink 
jet based, stereolithography). 
 
Currently there are five main 3D bioprinting techniques and the advantages and 
disadvantages are summarized in Table 1;  
1) Sterolithography14,15 
2) Extrusion based16,17  
3) Laser assisted18,19 
4) Ink jet based20,21 
5) Nanobioprinting22,23 
 
1) Stereolithography, which uses a laser beam to polymerise photocurable resin layer-by-
layer, is regarded as the first 3D printing technique14. It was initially developed to create 
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high resolution rapid prototypes and therefore the cytotoxic components and lack of 
biocompatible resins has limited its utility in biofabrication15,. The ability of sterolithography 
in creating complex shapes has shown promise in the fabrication of anatomical models 
and indirect moulds24. Continuing improvements in biocompatibility and biodegradation of 
resins as well as cell encapsulation during processing makes stereolithography a 
promising bioprinting technology of the future25,26. 
 
2) Extrusion based bioprinting (e.g. bioplotting or fused deposition modelling) involves 
dispensing viscous bioink (biomaterials, biomolecules, cells) through a nozzle or 
syringe16,17,27. After printing the constructs can be solidified (i.e. gelled) either physically or 
chemically layer-by-layer which makes this technique slower than others e.g. laser 
assisted or ink jet based17,27,28. Despite relatively high shear and extensional forces or 
higher temperatures, cell viability in the tissue constructs is reported to be as high as 
90%29. One of the main drawbacks of extrusion based bioprinting is its reliance on optimal 
material viscosity, which when not achieved, can lead to leaks and affect resolution of the 
final tissue construct.  
 
3) Laser assisted bioprinting involves either trapping and depositing cells in a laser beam 
(i.e. laser-guided direct writing19) or inducing the transfer of material from a source film by 
a pulsed laser onto a nearby receptor substrate in the form of a microdroplet (i.e. laser-
induced forward transfer30). Laser assisted bioprinting is nozzle-free and therefore 
compatible with a wide range of biomaterial viscosities and avoids the clogging problems 
of extrusion based techniques31,32. Despite suggestions of lower cell viability than other 
techniques, laser assisted bioprinting has been shown to print mammalian cells without 
affecting function or causing DNA damage33,34.  
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4) Inkjet printing (e.g. thermal, piezoelectric) uses micro-droplets of cells for fast printing of 
high-resolution structures35. The major limitations are cell viability at higher temperatures 
and pressures during the printing process21,36 as well as nozzle clogging due to cell 
aggregation21 leading to low cell density within the tissue construct36. The ability of ink-jet 
printing to combine multiple cell types, its high resolution and ongoing research into 
increasing cell concentrations make this a promising technology for complex tissue 
printing37.  
 
5) The emerging technology of nanobioprinting uses either nanoscale surface 
modifications of scaffolds to increase cell-matrix interactions or incorporates nanoparticles 
into bioinks e.g. superparamagnetic iron oxide to non-invasively manipulate and track cells 
within tissue engineered structures e.g. using an external magnet22,23.  
 
The selection of 3D bioprinting technique depends on the size of the tissue construct, 
sensitivity of cell placement, biomaterials and biomolecules as well as the desired 
resolution of print. The first commercial 3D bioprinter and market leader is the Organovo 
Novogen MMX BioprinterTM, which is an extrusion-based technique that uses cellular 
spheroids as tissue building blocks (ivetech website). While each of the 3D bioprinting 
techniques demonstrates specific properties such as high resolution, low price, high safety 
profile and high throughput, it is clear that achieving more advanced applications in tissue 
engineering will require a combination of these processes. Our group routinely uses 
extrusion based 3D bioprinting due to a combination of in house expertise and familiarity 
with the process. 
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Applications 
 
Bioprinting for tissue assembly 
 
The bioprinting field spans from promoting endogenous self-repair to creating biomimetic 
tissues for use in reconstructive surgery38. The traditional approach to tissue assembly has 
been to seed solid but porous scaffolds with a cell suspension (Table 2), with the porosity 
often achieved by particulate leeching or electrospinning39,40. This results in variable 
control over pore size, shape and interconnectivity, which are key factors influencing cell 
migration and proliferation41. Other methods of tissue assembly have included layering or 
rolling42,43, cell encapsulation within hydrogels44 and scaffold free cell patterning for tissue 
self-assembly45,46 (Table 2). The major limitations to all these approaches are a lack of 
control over cell-to-cell contact and microarchitecture, which are the key determinants of 
cell function47 as well as supply of nutrients and removal of waste products due to a lack of 
vascularity, restricting the final size of the constructs48,49. 
 
3D bioprinting offers the potential of biofabricating biological structures with a prescribed 
macro- (overall patient-specific shape), micro- (composition and arrangement of 
extracellular matrix affecting pore size and shape) and nanostructure (nanotopography 
and biomolecule attachments for optimal cellular interaction) to more closely replicate 
native tissue anisotropy6,10 (Figure 4). 3D microenvironments which provide optimal cell-
cell and cell-matrix interactions are critical for cell adhesion, proliferation, and 
differentiation and hence tissue regeneration50 (Figure 4). The potential benefits of 
bioprinting over other types of tissue assembly include repeatability, customization 
(personalised medicine), vascularization, high-resolution manufacture, automation and 
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ability to scale up production51,52 (Table 2). These features may provide the key for 
successful clinical translation.  
 
Bioprinting for reconstructive surgery  
 
Bioprinting may be used to pattern cells, scaffolds and biomolecules but there are different 
approaches on how to form the final tissue construct11.The tissue micro and 
macroarchitecture is either matched completely to the functional native tissue from the 
start, known as biomimicry12,53 or the patterning of cells and biomolecules on supporting 
bioactive structures is used to drive the cells towards tissue formation based on embryonic 
tissue self-assembly54. A third approach is to use biopatterning to reproduce the smallest 
structural and functional component i.e. mini-tissue building blocks with larger constructs 
assembled by either biomimicry or self-assembly52,55 (Table 3). These strategies are 
currently being used singly or in combination to bioprint a variety of tissue types for 
potential future use in reconstructive surgery (Table 4).  
 
Most research has focused on bioprinting bone using three main techniques (ink jet based, 
stereolithography and fused deposition modelling), often using biomaterials alone without 
cells56,57. Choosing medical grade materials allows swift clinical translation to demonstrate 
integration and bony consolidation, bypassing the need to extensive in vitro and animal 
work58, but can limit development of the field by excluding favourable candidates which are 
not yet medical grade. Other tissue types in the early stages of research include 
cartilage59,60,61, muscle62,63, nerve21,64, fat34,65 and skin66,67 (Table 4). The panacea would 
be to one day bioprint composite vascularized flaps with their own internal 
microvasculature that could be directly anastomosed to the recipient’s blood vessels using 
microsurgical techniques, obviating the need for donor sites (Figure 5). It is perhaps this 
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exciting potential that has spurred on many scientists to investigate the capability of 
bioprinting microvascular networks, using a variety of support and sacrificial materials to 
allow the creation of interconnecting channels36,46(Table 4).  
 
Challenges 
 
Biological 
 
Simply depositing cells, scaffolds and biomolecules in a spatially controlled manner is not 
sufficient to create durable native-like tissue for transplantation. The transition of 
mechanically weak 3D bioprinted neo-tissue constructs to native-like surgically relevant 
tissue is a vital step in the post-printing process and is the main factor limiting successful 
clinical translation52,68. This transition into functional tissue can either be undertaken in 
vitro during several months of bioreactor-based culture using a variety of physiological 
conditions and growth factor combinations69 or in vivo through implantation of the 
construct allowing in situ growth that supersedes the natural tendency for degradation70. 
Identification of optimal “maturogenic factors” for different tissue types will be pivotal in 
driving progress in this field68 (Figure 6).  
 
One of the biggest challenges to the size and complexity of tissue engineered constructs 
is believed to be due to a lack of vasculature, relying instead on the porous structure of 
scaffolds to allow flow of nutrients and waste until extrinsic neovascularization develops 
from the host71. Preliminary evidence has shown that increasing pore size or adding 
angiogenic growth factors e.g. VEGF promotes natural angiogenesis and inosculation but 
this is too slow to allow any meaningful increase in the size and complexity of the tissue 
construct46. Although there has been some progress in bioprinting isolated cell lined 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 14 
microfluidic channels, most have been proof of concept in vitro studies rather than creating 
functional blood vessel and capillary networks in vivo capable of supporting nutrient 
provision to an engineered piece of tissue36,46.  
 
Printing complex composite tissue has other unique challenges, such as long 
biomanufacture times with resulting reduction in cell viability72, cellular dedifferentiation 
with loss of regenerative potential73, release of acidic by-products from degradation of 
biomaterials74 as well as non-homogenous matrix synthesis, lacking post-printing tissue 
remodelling and hence poor long-term maintenance of mechanical strength75.  
 
Technological 
 
Ensuring high resolution or ‘fidelity’ of bioprinted constructs and finding the optimal 
printable support material remain the major hurdles for printing complex biological 
structures76. Higher resolutions not only allow better replication of native architecture but 
can also control pore size and interconnectivity which is important when considering that 
diffusion distances of over 400-500um may limit oxygen transport and hence cell viability9. 
Currently stereolithography and ink jet based techniques provide some of the best 
available resolution but are limited by the lack of appropriate biomaterials, lower cell 
viabilities and poor mechanical strength. Laser-assisted bioprinters are able to print at a 
microscale resolution but preparation of individual ribbons for deposition can be time 
consuming and not cost effective30. Mathematical modelling may help with increasing 
resolution whilst optimising the printability of tissue constructs by adjusting for a variety of 
variables simultaneously e.g. cell seeding density, porosity54. Automated robotic systems 
may provide cost-effective and potentially scalable means of automating the bioprinting 
process for commercial biofabrication77.  
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Regulatory 
 
Clinical translation will involve ensuring the safety of the bioprinted tissue, particularly with 
respect to controlling growth potential and practicalities such as availability of stem cell 
banks, upscaling, sterility and storage of tissue engineered constructs2.  
Biomanufacture, as with other tissue engineered products, will need to comply with current 
Good Manufacturing Practice regulations and gain The Food and Drug Administration 
(FDA) or European Medicine Agency (EMA) approval78. Bioprinted constructs that contain 
cells are classified as combination products by the FDA and advanced therapy medicinal 
products by the EMA and require rigorous clinical trials testing prior to approval for routine 
use78,79. The main hurdle will be to standardize, validate and continuously monitor 3D 
bioprinting manufacture from the design to production stage, which is extremely difficult for 
a customizable and hence intrinsically variable process41.  
 
Conclusion 
 
The 3D bioprinting field is a rapidly expanding area of worldwide research intimately linked 
with tissue engineering. Successful clinical translation would have a significant impact on 
the morbidity and mortality of patients and the healthcare economy. The ultimate success 
of this platform technology depends on answers to the fundamental scientific questions 
regarding the correct blend of cell source, suitable printable scaffold and ideal 
microenvironment to mimic native tissue anisotropy; if in fact these can be answered at all. 
3D bioprinting is still in its infancy, highlighted by the fact that most current studies have 
been in vitro proof of concept only, with no widely available 3D bioprinted tissues on the 
market. Given the future potential and synergistic goals of bioprinting and reconstructive 
surgery in restoring ‘form and function’, we propose that plastic surgeons should be well 
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versed in contemporary 3D bioprinting principles and are well placed to help direct 
research in this developing field to ensure it maintains clinical relevance, without being 
seduced by hope and hype. Overcoming the biological, technological and regulatory 
challenges to ensure successful clinical translation will only be possible via an integrated 
approach with a combination of technologies from the fields of engineering, biomaterial 
science, cell biology and reconstructive microsurgery. 
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Figure Legends 
 
Figure 1. 3D Bioprinting Process. 1. Clinical defect. 2. Image acquisition (CT or 3D 
scanning). 3. Image post-processing (3D model converted to STL; standard tessellation 
language). 4. 3D bioprinting (e.g. bioplotting or nozzle-based). 
 
Figure 2. 3D Bioprinter Hardware; a) Swansea University experimental 3Dynamic 
Workstation Omega dual extrusion 3D bioprinter (extrusion based), b) 3D bioprinting of 
geometrical shapes, and c) auricular cartilage containing human nasoseptal chondrocytes. 
 
Figure 3. 3D Bioprinter Software; a) Autodesk Inventor software to design 3D model 
based on patient photographs, b) STL file of auricular cartilage on Cura software, which is 
used to create G-code instructions for the 3D printer. 
 
Figure 4. The advantages of 3D bioprinting of scaffold, cellular and biomolecule 
components for tissue engineering. 
 
Figure 5. Progress towards panacea of bioprinting composite pre-vascularized flaps for 
reconstructive microsurgical implantation.  
 
Figure 6. Current technological, biological and regulatory challenges in 3D bioprinting 
research 
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Tables 
 
Table 1. Summary of biocompatible 3D printing technologies – principles, advantages and 
drawbacks. 
3D bioprinter 
Summary of 
technique 
Advantages Disadvantages References 
Stereolithography  
e.g. 
Photosolidification, 
resin printing 
Polymerisation of 
photocurable resin layer 
by layer 
- Extremely high resolution with 
ability to create complex shapes 
and microarchitecture 
- Few suitable biomaterials are 
stable during polymerisation 
- Significant non-degradable 
components 
- Poor mechanical properties 
3,14,15
 
Laser assisted  
e.g.  Laser guided 
direct writing, laser 
induced forward 
transfer 
  
Deposition of cells either 
in a laser beam or using 
pulsed laser for transfer 
- High resolution 
- Avoids problems of clogging 
- Compatible with wide range of 
biomaterial viscosities 
- High cell density 
- Mesenchymal stem cells retain 
trilineage potential  
- Medium-fast 
- Lower cell viability 
- Limited construct size 
- Not cost effective 
3,18,19,30,31,32,
 
Extrusion based  
e.g. Bioplotting, fused 
deposition modelling, 
pneumatic vs. 
biomechanical 
Viscous liquid or molten 
material extruded through 
nozzle or syringe as a 
continuous strand of 
individual dots 
- Deposit clusters of cells 
- Scaffolds for soft tissue 
engineering  
- Possible to control pore size, 
morphology and 
interconnectivity 
- Material flexibility  
- Material viscosity and potential 
for leaks can affect resolution 
- Limitation on complexity of 
shapes with overhang 
- Problems with cell viability with 
sheer or high temperature 
- Limited mechanical stiffness 
- Slow 
16,17,27
 
 
Ink jet based 
e.g. thermal 3D ink jet 
bioprinting, 
piezoelectric 
dispensing 
Photopolymer-based bio-
ink is jetted by an inkjet 
and cured with UV light 
- High resolution  
- Multi – “colour” printing, each 
ink (cellular, ECM, biomolecule) 
positioned in precise location 
i.e. introduce gradients  
- Complex scaffolds with 
microstructure control (internal 
channels/overhangs) 
- Fast 
- Potential for cell death at 
higher temperatures and 
pressures 
- Smaller nozzles prone to 
clogging 
- Organic solvents as binders 
can dissolve polymers 
- Limited available pore sizes 
20,35
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Nano scale  
e.g.  Dip 
pen 
nanolithogr
aphy 
Electron beam  
polymerisation or atomic 
force  
microscope probes 
relying on capillary action 
or electrostatic 
interactions 
- Allows scaffold surface 
modification on the nanoscale 
for additional functionality (e.g. 
biomolecule attachment for cell 
adhesion, proliferation, and 
differentiation) 
- Nanobioprinting can 
manipulate and track bioactive 
factors and cells within tissue 
engineered constructs 
- Nanoparticles can lose viability 
post printing 
- Currently little known about 
effect of nanotopography and 
nanoparticle effect on cell  
behaviour 
22,23
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Table 2. Tissue engineering techniques to assemble cells, biomaterials and biomolecules.  
 
  
Tissue assembly  
technique 
Principles Advantages Disadvantages References 
Cell seeding 
i.e. top-down 
 approach 
Cell seeding of scaffolds 
(synthetic, natural or 
decellularised), followed by 
maturation in bioreactor 
• Feasible for thin or avascu-
lar tissues e.g. skin, carti-
lage 
• Control macrostructure 
• Lack of precision over cell 
placement 
• Limited vasculogenesis 
• Problems with mass 
transfer (i.e. nutrients and 
waste products) 
47
 
 
Self-assembly 
i.e. bottom-up 
approach 
Pattern cells to promote 
cellular self-sorting, self-
assembly and ECM 
production i.e. mimic 
postnatal tissue development 
• Control microstructure  
• Cell driven process 
  
• In depth understanding of 
embryological tissue/organ 
development  
• Size of construct dependent 
on angiogenesis 
• Slow to scale up 
45,46
 
Layering/rolling 
Cell sheets stacked to form a 
thicker tissue or rolled to 
form hollow tubes 
• Pattern multiple cell types • Cohesiveness depends on 
ECM production by cells 42,43
 
Cell-laden 
hydrogels/microgels 
Hydrogels used as artificial 
ECM to encapsulate cells 
• Provide scaffold for cell 
proliferation, differentiation 
and ECM production 
• Size constructs limited by 
mass transfer of metabolites 44
 
Electrical cell  
guiding 
Electromagentic forces to 
pattern cells 
• Position with single-cell 
resolution 
• Lack control over ECM 
deposition 
19
 
3D Bioprinting 
Cells, scaffold and 
biomolecules deposited in a 
precise 3D structure 
• Simultaneous control of 
micro and macrostructure 
• Micro- and nano-structuring 
topography and 
biomolecules can influence 
cell differentiation 
• Potential to create complex 
tissue and vascularity 
• Automated high resolution 
manufacture with scalability 
• In depth understanding of 
native microarchitecture 
required 
• Need biocompatible bioinks  
51,52
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Table 3. Principles of tissue regeneration using 3D bioprinting (adapted from Murphy and 
Atala 201411) 
Bioprinting approach Principles Requirements References 
Biomimcry 
Identical reproduction of 
tissue microarchitecture 
• Cells, ECM, biomolecules 
• High printing resolution 
• In depth understanding of 
microenvironment 
11,12,53
 
Autonomous 
self-assembly 
Based on embryonic tissue 
development, cell as the 
primary driver of tissue 
formation 
• Cells, biomolecules 
• Knowledge of embryonic tissue 
development 
54,55
 
Mini-tissues 
Reproduction of the smallest 
structural and functional 
component, larger construct 
assembly by biomimicry or 
self-assembly 
• High printing resolution of mini-
tissues 
• Methods of macro assembly 
  
52,55
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Table 4. Summary of progress in 3D bioprinting for engineering different tissue types. 
PCL, polycaprolactone; PLGA, poly(lactic-co-glycolic acid); TCP, tri-calcium phosphate; 
PEG, poly(ethylene glycol); PU, polyurethane; HA, hydroxyapatite; CNTF, ciliary 
neurotrophic factor; VEGF, vascular endothelial growth factor; BMP-2, bone morphogenic 
protein 2; TGFb1, transforming growth factor beta 1; FGF2, fibroblast growth factor 2. 
Tissue 
Type 
Cell Type 
Biomaterial +/-
Biomolecules 
Bioprinting Technique Outcome 
In vivo/ 
vitro 
Ref 
CARTILAGE 
Articular  
Chondrocytes  
(bovine) 
Calcium polyphosphate Ink jet based 
Good compressive strength and 
supported cartilage formation 
In vitro 59
 
Articular  
Chondrocytes 
(bovine) 
Poly (trimethylene carbonate) Stereolithography 
Constructs supported differentiated 
chondrocyte phenotype 
In vitro 80
 
Articular 
Chondrocytes 
(porcine) 
PLGA and type II collagen 
Extrusion based (fused 
deposition modelling) 
Good chondrocyte distribution and 
neocartilage formation 
In vitro 60
 
Articular 
Mesenchymal stem 
cells (human) 
Scaffold free  
Laser assisted (laser induced 
forward transfer) 
MSC viability and bone and cartilage 
differentiation 
In vitro 63
 
Articular 
Chondrocytes 
(human) 
PEG dimethacrylate Ink jet based 
Osteochondral plugs with good 
compressive strength 
In vitro 81
 
Fibro-
cartilage 
Mesenchymal stem 
cells (human) 
Methacrylated gelatin 
BMP2 and TGFb1 
Extrusion based (nozzle 
extrusion of micro droplets) 
Anisotropic fibrocartilage, 
chondrogenic and osteogenic 
differentiation 
In vitro 82
 
BONE 
Calvarial None Monolithic monetite  Ink jet based 
Good integration between the implant 
and the calvarial bone 
In vivo (rabbit) 56
 
Calvarial None 
PCL/PLGA bounded with 
TCP 
Extrusion based (fused 
deposition modelling) 
Good bone formation In vivo (rabbit) 57
 
Calvarial 
C2C12 progenitor 
cells (mouse) 
DermaMatrix 
BMP2 with noggin 
Ink jet based Spatial control of bone formation 
In vitro and in 
vivo (mouse) 
83
 
Calvarial None 
PCL-TCP biodegradable 
scaffold  
  
Extrusion based (fused 
deposition modelling) 
After 6 months the implant was well 
integrated with bone consolidation on 
CT 
In vivo (human) 58
 
Craniofacial 
/  
Bone 
spacers 
None 
Polymethylmethacrylate 
filament 
Extrusion based (fused 
deposition modelling) 
Feasibility of biofabrication of 
customised 3D structures with 
variable porosity  
In vitro 84
 
Tibial and 
Maxillary 
C2C12 pre-
myoblastic cell line 
Ceramic 
BMP2 
Ink jet based 
Customisable, biocompatible, 
osteoinductive scaffold  
In vitro and in 
vivo (rabbit and 
porcine) 
85
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Femoral None 
PLGA/β-TCP/HA 
nanocomposite 
Extrusion based (fused 
deposition modelling) 
Good integration into host bone In vivo (rabbit) 86
 
Femoral None 
Calcium phosphate and 
collagen scaffold 
Ink jet based 
Tween 80 improved printing, implants 
osteoconductive 
  
In vivo (mouse) 87
 
Non-specific 
Osteosarcoma 
MG63 cells  
(human) 
Electrospun PCL as substrate Laser assisted  
Supported cell survival and enhanced 
cell proliferation 
In vitro and in 
vivo (mouse) 
88
 
Non-specific None Calcium phosphate granules  Stereolithography 
Mechanical properties can be 
adjusted via inner channel structure 
and hydroxyapatite and tri-calcium 
phosphate ratios 
In vitro 89
 
Non-specific None HA and TCP Stereolithography 
Good biocompatibility and 
osteoinductivity 
In vivo (rat) 90
 
Non-specific None 
Polylactic acid and a 
bioactive CaP glass 
Extrusion based  
Compression strength is dependent 
on scaffold geometry and the 
presence of glass 
In vitro 91
 
Non-specific 
Osteoblasts 
(human) 
PLGA Stereolithography 
Compatible with osteoblast 
proliferation, mechanically similar to 
trabecular bone 
In vitro 92
 
Non-specific 
Mesenchymal stem 
cells (goat) 
BMP2 loaded gelatin 
microparticles 
Extrusion based (pneumatic) 
Osteogenic differentiation and bone 
formations, increased by slow release 
of BMP2  
In vitro and in 
vivo (mouse and 
rat) 
93
 
Non-specific 
Mesenchymal stem 
cells (human) 
Acrylated PEG hydrogel with 
bioactive glass and HA 
Inkjet  based 
Osteogenic and chondrogenic 
differentiation with minimal printhead 
clogging 
In vitro 94
 
FAT 
  
Adipose derived 
stem cells (human) 
Alginate hydrogel spheroids Extrusion based 
Uniform dimensions of bioprinted 
spheroids 
In vitro 65
 
  
Adipose derived 
stem cells and 
endothelial colony-
forming cells 
(human)  
Fibrinogen and hyaluronic 
acid solution 
Laser assisted (laser induced 
forward transfer) 
3D cell arrays generated as proof of 
concept, resulting in formation of 
vascular-like network  
In vitro 34
 
NERVE 
  
Primary embryonic 
hippocampal and 
cortical neurons  
(rat) 
Fibrin gels Inkjet based 
Healthy neuronal phenotypes and 
electrophysiological characteristics 
post-printing 
In vitro 
21
 
 
 
  
Neural stem cell 
(rat) 
Poly-acrylamide-based 
hydrogel with FGF2 or CNTF 
Inkjet based 
Printed gradient of increasing levels 
of CNTF showed a linear increase 
astrocytic differentiation 
In vitro 64
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Neural stem cell 
(murine) 
Polyurethane 
thermoresponsive hydrogels  
Extrusion based (fused 
deposition modelling) 
Excellent proliferation, differentiation 
and repair in neural injury model 
In vitro and in 
vivo (zebrafish) 
95
 
  
Mesenchymal stem 
cells and Schwann 
cells (murine) 
Agarose rod supports Inkjet printing 
Functional nerve repair on 
electrophysiological testing 
In vitro and in 
vivo (rat) 
96
 
  
Neural stem cell 
(murine) 
Collagen and VEGF-
releasing fibrin gel scaffolds 
Extrusion based (pneumatic) 
Sustained release of VEGF promoted 
cell migration 
In vitro 97
 
VASCULATURE 
  
Microvascular 
endothelial cells 
(human)  
Fibrin  Inkjet based (thermal) 
Cells aligned themselves inside the 
channels and proliferated to form 
microvasculature channels  
In vitro 36
 
  
Mesenchymal stem 
cells and umbilical 
vein endothelial 
cells (human)  
Polyester urethane urea 
support 
Laser assisted (laser induced 
forward transfer)  
Enhanced capillary density and 
integration of human cells into murine 
vascululature 
In vitro and in 
vivo (rat) 
98
 
 
 
  
Umbilical vein 
smooth muscle 
cells and fibroblasts 
(human) 
Agarose rods supports Extrusion based 
Engineered tubes of multiple layers 
and complex branching geometry 
In vitro 
46
 
 
 
  
Umbilical vein 
endothelial cells 
and umbilical vein 
smooth muscle 
cells (human) 
Matrigel support Laser assisted 
Self-assembling  
lumen networks 
In vitro 99
 
  
Umbilical vein 
endothelial cells 
and fibroblasts 
(human)  
Aqueous plutonic F127 
support and gelatin 
methacrylate cell carrier 
Extrusion based (nozzle) 
Fesibility of multinozzle printing, 
scalable with multiple cell types  
In vitro 100
 
  
Mesenchymal stem 
cells (human) 
Alginate, gelatin and 
hydroxyapatite hydrogel 
Extrusion based (nozzle) 
Hollow channels generated, 
orientation influenced size and shape 
of channels  
In vitro 101
 
  
Umbilical vein 
endothelial cells 
(human) 
Carbohydrate glass support Extrusion based (nozzle) Creation of rigid filament networks  In vitro 102
 
  
Hepatoma cells and 
intestinal epithelial 
(human), fibroblasts 
(murine) 
Hyaluronic acid metacrylate 
and gelatin ethanolamide 
methacrylate  
Extrusion based (nozzle) 
Viable cells that remodelled vessel to 
a naturally secreted extracellular 
matrix 
In vitro and In 
vivo (mouse) 
103
 
  
Umbilical vein 
smooth muscle 
cells (human) 
Sodium alginate Extrusion based (nozzle) 
Good proliferation and deposition  of 
smooth muscle matrix and collagen 
In vitro 104
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  Fibroblasts (human) 
Collagen scaffold, gelatin 
support 
Extrusion based (pneumatic) 
Higher cell viability in constructs with 
microfluidic channels 
In vitro  105
 
  None Alginate with gelatin support Ink jet based 
Tissue-like microvasculature capable 
of supporting physiological flow rates 
In vitro 106
 
SKIN 
  
Keratinocytes and 
fibroblasts (human) 
Type I collagen hydrogel Extrusion based (pneumatic) 
Dermal and epidermal layers, >95% 
cell viability 
In vitro 66,67
 
  
Keratinocytes and 
fibroblasts (human) 
Fibrin and type I collagen 
hydrogel 
Ink jet based (in situ) 
Improved healing and less 
contracture than controls 
In vivo (mouse) 107
 
  
Amniotic fluid 
derived and 
mesenchymal stem 
cells 
Fibrin-collagen gel Ink jet based (pneumatic) 
Improved wound healing with 
bioprinted amniotic derived stem cells 
In vivo (mouse) 108
 
  
Fibrobasts and 
keratinocytes 
(human) 
Matriderm support Laser assisted 
Multilayered epidermis with 
vascularisation from wound bed 
In vitro and vivo 
(mouse)  
109
 
  
Fibrobasts, 
keratinocytes, 
mesenchymal stem 
cells (human) 
Collagen hydrogels 
Laser assisted (laser induced 
forward transfer) 
Multilayered skin, cellular DNA, 
differentiation and proliferation not 
affected 
In vitro and in 
vivo (mouse) 
110,111
 
MUSCLE 
  
Muscle derived 
stem cells (murine) 
Fibrin scaffolds, BMP2 Inkjet based 
Formation of myotubes, BMP2 
controled myogenic and osteogenic 
micro-patterning  
In vitro 62
 
  
Myoblasts and 
fibroblasts (human) 
PU (with myoplasts) or PCL 
(with fibroblasts)  
Extrusion based 
High cell viability, differentiation and 
initial developments of  muscle 
tendon unit 
In vitro 63
 
  
Smooth muscle 
cells (rat) 
Collagen  Extrusion based  Long term cell viability in culture In vitro 112
 
  Myoblasts (murine) Alginate and gelatin Extrusion based 
Mechanical properties altered by 
structure design and culture 
In vitro 113 
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